OS THERAPIES INCORPORATED Research and Development Expense
OS THERAPIES INCORPORATED (OSTX) reported Research and Development Expense of $6.07 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- OS THERAPIES INCORPORATED research and development expense for the quarter ending 2026-06-30 was $6.07M, a 143.03% increase year-over-year.
- OS THERAPIES INCORPORATED research and development expense for the quarter ending 2026-03-31 was $7.35M, a 461.56% increase year-over-year.
- OS THERAPIES INCORPORATED research and development expense for the quarter ending 2025-12-31 was $8.80M, a 910.57% increase year-over-year.
- OS THERAPIES INCORPORATED research and development expense for the quarter ending 2025-09-30 was $3.76M, a 210.30% increase year-over-year.
- OS THERAPIES INCORPORATED research and development expense for fiscal 2025 was $16.36M, a 476.27% increase from fiscal 2024.
- OS THERAPIES INCORPORATED research and development expense for fiscal 2024 was $2.84M, a 11.75% decline from fiscal 2023.
- OS THERAPIES INCORPORATED research and development expense for fiscal 2023 was $3.22M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.07M 10-Q · filed 2026-08-14 | $13.43M 10-Q · filed 2026-08-14 | $22.22M derived: sum of 3 quarters · filed 2026-08-14 | $25.98M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $7.35M 10-Q · filed 2026-05-18 | $16.15M derived: sum of 2 quarters · filed 2026-05-18 | $19.90M derived: sum of 3 quarters · filed 2026-05-18 | $22.40M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $8.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $12.55M derived: sum of 2 quarters · filed 2026-03-31 | $15.05M derived: sum of 3 quarters · filed 2026-08-14 | $16.36M 10-K · filed 2026-03-31 |
| 2025-09-30 | $3.76M 10-Q · filed 2025-11-14 | $6.25M derived: sum of 2 quarters · filed 2026-08-14 | $7.56M 10-Q · filed 2025-11-14 | $8.43M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $2.50M 10-Q · filed 2026-08-14 | $3.81M 10-Q · filed 2026-08-14 | $4.68M derived: sum of 3 quarters · filed 2026-08-14 | $5.89M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.31M 10-Q · filed 2026-05-18 | $2.18M derived: sum of 2 quarters · filed 2026-05-18 | $3.39M derived: sum of 3 quarters · filed 2026-05-18 | $3.79M derived: sum of 4 quarters · filed 2026-05-18 |
| 2024-12-31 | $870.47K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.08M derived: sum of 2 quarters · filed 2026-03-31 | $2.48M derived: sum of 3 quarters · filed 2026-03-31 | $2.84M 10-K · filed 2026-03-31 |
| 2024-09-30 | $1.21M 10-Q · filed 2025-11-14 | $1.61M derived: sum of 2 quarters · filed 2025-11-14 | $1.97M 10-Q · filed 2025-11-14 | $2.99M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $396.57K 10-Q · filed 2025-08-18 | $758.38K 10-Q · filed 2025-08-18 | $1.78M derived: sum of 3 quarters · filed 2025-08-18 | $2.23M derived: sum of 4 quarters · filed 2025-08-18 |
| 2024-03-31 | $361.81K 10-Q · filed 2025-05-15 | $1.38M derived: sum of 2 quarters · filed 2025-05-15 | $1.84M derived: sum of 3 quarters · filed 2025-05-15 | $2.83M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.47M derived: sum of 2 quarters · filed 2025-03-31 | $2.47M derived: sum of 3 quarters · filed 2025-03-31 | $3.22M 10-K · filed 2025-03-31 |
| 2023-09-30 | $454.50K 10-Q · filed 2024-11-15 | $1.45M derived: sum of 2 quarters · filed 2024-11-15 | $2.20M 10-Q · filed 2024-11-15 | |
| 2023-06-30 | $992.90K 10-Q · filed 2024-08-14 | $1.74M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $753.78K 10-Q · filed 2024-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |